

PRIORITISE AND FUND TRIKAFTA FOR 2-5 YEAR OLDS



The earlier children receive Trikafta, the better their long-term health outcomes.



Pharmac's Respiratory Advisory Committee noted that:

- Trikafta in CF is a lifelong preventative treatment.
- There is **no biologic or evidence-based reason** to commence treatment at six years of age.
- The CF disease trajectory for CF is generally set before the age of six.



Funding Trikafta for 2 to 5 year olds is an investment in our children's future to live well.



More than 40 countries now have access in place for 2 to 5 year old children with CF, making New Zealand further out of step with the rest of the world.



Have your voices heard

We collectively act together, with the same message, and powerful stories so we can have our voices heard.

These letters provide a way for families to have a say in the funding assessment of Trikafta for 2 to 5 year old children.

WHAT WE NEED YOU TO DO

- Download the letter template or write your own
- Send your letter to CFNZ at community@cfnz.org.nz by Friday 29 August 2025

TIPS FOR THE STRUCTURE OF YOUR LETTER

- Tell them how CF affects your child, your family, and whanau
- Tell them what impact the delay in funding Trikafta for 2 to 5 year olds is having on you
- Tell them what Trikafta would mean for you, and how it would change your child's life
- Keep it short and to the point, make sure you sign it

THINGS TO CONSIDER WHEN WRITING YOUR LETTER

- Juggling life with medication, nutrition and treatments
- Constant worry about keeping them safe from coughs, colds, and flu
- Delay starting school
- Unable to go into daycare

- Parent/s unable to work
- Hospitalisations
- IV antibiotics
- Chest infections
- Impact on daily life
- Treatments (nebulising, sinus rinses), and medications (pancreatic enzymes, antibiotics)

